Evidence map›Paper›PMID 40467832›Full record

ArticleDrug safety2025

An Evaluation of Duplicate Adverse Event Reports Characteristics in the Food and Drug Administration Adverse Event Reporting System.

Scott Janiczak, Sarah Tanveer, Karen Tom, Rongmei Zhang, Yong Ma, Lisa Wolf, Monica A Muñoz

Erratum issuedAbstract read
In one paragraph

Article in Drug safety, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Comparative pharmacovigilance of Levodopa and Pramipexole: a disproportionality analysis of the FAERS database.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Scott JaniczakOffice of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD, USA. Scott.Janiczak@fda.hhs.gov.ORCID http://orcid.org/0009-0005-8794-9749
Sarah TanveerOffice of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD, USA.
Karen TomOffice of Strategic Partnerships and Technology Innovation, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD, USA.
Rongmei ZhangOffice of Biostatistics, US Food and Drug Administration, Silver Spring, MD, USA.
Yong MaOffice of Biostatistics, US Food and Drug Administration, Silver Spring, MD, USA.
Lisa WolfOffice of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0002-7372-6051
Monica A MuñozOffice of Surveillance and Epidemiology (OSE), Center for Drug Evaluation and Research (CDER), US Food and Drug Administration, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0001-9754-1986

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) receives duplicate reports of adverse events associated with drug and therapeutic biological products. Duplicate reports, defined as multiple reports of the same adverse event(s) related to the administration of the same marketed product(s) to the same individual patient at a particular point in time, may be received in FAERS for many reasons. The presence of duplicate reports can negatively impact public health surveillance efforts by impeding both safety signal identification and signal evaluation.

objectivesTo characterize the features and contributing factors associated with duplicate reports in FAERS.

methodsWe manually assessed a convenience sample of individual case safety reports (ICSRs) for duplication, resulting in two data sets: one consisting of non-duplicate reports and one with duplicate reports. We then compared key features of these two datasets, including both structured and unstructured data fields. Key comparison features included: report and reporter type, country of report origin, data source for report, and outcome. In addition, we evaluated information similarity of reports for seven data elements (e.g., age, sex, suspect products) within sets of duplicates using both structured and unstructured fields. We used pairwise sentence bidirectional encoder representations from transformers (SBERT) cosine similarity scores to examine free-text narrative similarity.

resultsAmong the 2297 reports in the sample, 901 (39%) were classified as duplicates, consisting of 237 unique duplicate sets. Compared to non-duplicate reports, duplicates were more likely to be foreign reports (82% versus 37%), reported by healthcare professionals (89% versus 68%), mention other regulatory authority databases (42% versus 11%), describe published case reports (34% versus 11%), or have a serious outcome (97% versus 83%) (p < 0.0001). Within sets of duplicates (n = 237), coded information was frequently different, with only 16% (n = 39) having concordance of all 7 data elements. The narrative was highly similar among most sets of duplicates; we found that the median similarity score for the duplicate pairs was 0.87 compared to 0.48 for non-duplicate pairs.

conclusionsWe observed differences in the attributes of and potential contributors to duplicate reports in FAERS that may inform duplicate prevention, detection, and management strategies. However, further studies are needed to better understand the implications of these findings and how potential regulatory changes and technological advances can be leveraged to further address duplicate reporting in adverse event reporting systems.

Indexed as

Adverse Drug Reaction Reporting SystemsDrug-Related Side Effects and Adverse ReactionsUnited States Food and Drug AdministrationDatabases, FactualFemaleHumansMaleUnited States

Identifiers

PMID40467832
PMCPMC12423208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.